Applied Imaging Solutions LLC

Applied Imaging Solutions LLC, a for-profit manufacturer based in Quincy, Massachusetts, develops interpretable artificial intelligence and deep learning systems integrated with hyperspectral imaging platforms for real-time bioreactor monitoring and control, operating exclusively as a federal grant recipient under the National Institute of Standards and Technology.

The vendor's federal footprint is narrowly concentrated: all three awards in the source data derive from NIST under the Science, Technology, Business and/or Education Outreach program (CFDA 11.620), with no contract prime or subcontract work. Applied Imaging Solutions LLC holds two prime cooperative agreements and one sub-award, totaling $652 thousand in combined obligation. The Phase I Cooperative Agreement from NIST, awarded May 15, 2024 and completing February 15, 2025, funded feasibility research on an AI deep learning system for real-time detection of cell and metabolite properties in biopharmaceutical bioreactor environments, with a sub-award for algorithm development and data analysis to an unnamed subawardee. The Phase II Cooperative Agreement, awarded October 1, 2025 and completing September 30, 2027, carries $400,000 in NIST funding and advances the research into an interpretable AI and deep learning system integrated with short-wave infrared hyperspectral imaging to analyze Chinese hamster ovary cells, detecting cell viability, glucose and lactate concentrations, and monoclonal antibody quality attributes including glycosylation, aggregation, and deamidation for real-time online quality control. The Phase II award includes a sub-award to the University of Maryland, College Park. Applied Imaging Solutions LLC also appears as a sub-recipient under a February 4, 2026 grant from the University of Delaware on an in-line contactless label-free short-wave infrared flow cytometer project for biotherapeutic process monitoring and control. The vendor's intended beneficiaries span advanced biologics manufacturers, healthcare information technology companies, and the life sciences industry. One award (the Phase II NIST cooperative agreement) reaches ultimate completion within the next twenty-four months and faces recompete.